ZGNX News and Press, Zogenix Inc. From 04/22/21

Zogenix (ZGNX) announces new data showing the positive impact of treatment with Fintepla (fenfluramine) oral solution on everyday executive function for children and young adults with Lennox-Gastaut syndrome ((LGS)), a rare, severe epilepsy. Treatment continued for a combined 14-week titratio...

LGS is one of the most challenging developmental and epileptic encephalopathies to manage because of high seizure frequency and significant neurodevelopmental impairment. More LGS study patients treated with FINTEPLA (fenfluramine) showed improvement in each of the BRIEF 2 index...

EMERYVILLE, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the first quarter ended March 31, 2021 and host a corporate update conference ca...

Zogenix (ZGNX) announces new findings from an investigator-initiated study designed to assess caregivers’ perspectives on the long-term seizure- and non-seizure-related benefits of FINTEPLA (fenfluramine) on patients with Dravet syndrome.Caregivers of patients who received FI...

Seizure Related Benefits noted by caregivers included reduction in frequency, fewer triggers causing seizures, and shorter recovery time when seizure did occur. Non-Seizure benefits most commonly noted include improvements in executive functions such as cognition, learning, ...

EMERYVILLE, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Executive Vice Pres...

Following yesterday's announcement that the FDA issued a complete response letter for Nuplazid (pimavanserin) for a label extension, Mizuho analyst Vamil Divan has downgraded Acadia (ACAD) shares to neutral and lowered his price target to $25 from $37.He says the company is unlikely to win FD...

EMERYVILLE, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Executive Vice Pres...

Wall Street is betting on the biotech industry. Many biopharma stocks are close to developing drugs for chronic and life-threatening ailments. With impressive clinical trial results and growth potential, we believe stocks such as Immunovant (IMVT), Zogenix (ZGNX), and Spectrum Pharmaceuticals...

EMERYVILLE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Michael Smith, Executive Vice President, Chief Financial Officer, and Treasurer, will present a corpo...